TABLE 3

Poisson regression results detailing characteristics associated with successful treatment outcome

IRR (95% CI)aIRR (95% CI)#
Age years
 18–290.99 (0.80–1.23)1.03 (0.82–1.30)
 30–49ReferenceReference
 ≥500.78 (0.56–1.07)0.80 (0.59–1.09)
Sex
 FemaleReferenceReference
 Male0.81 (0.68–0.96)0.83 (0.71–0.98)
Resistance
 preXDR-TB (FLQ)0.80 (0.65–0.97)0.81 (0.67–0.99)
 preXDR-TB (SLI)0.94 (0.76–1.17)0.97 (0.80–1.17)
 XDR-TBReferenceReference
 Missing resistance report0.62 (0.50–2.50)0.68 (0.20–2.32)
Weight kg
 ≤501.05 (0.88–1.24)1.02 (0.86–1.20)
 >50ReferenceReference
HIV status
 NegativeReferenceReference
 Positive1.14 (0.94–1.39)1.18 (0.98–1.42)
 HIV viral load >1000 copies0.78 (0.55–1.10)0.87 (0.62–1.20)
Bedaquiline
 Completed 24 weeks1.05 (1.03–1.08)1.05 (1.03–1.08)
 IncompleteReferenceReference
Other drugs included in the background regimen
 Clofazimine1.01 (0.81–1.27)0.94 (0.76–1.16)
 Kanamycin0.87 (0.69–1.08)0.96 (0.74–1.24)
 Levofloxacin1.04 (0.82–1.32)0.99 (0.79–1.24)
 Linezolid1.15 (0.95–1.39)1.14 (0.94–1.39)

Data in bold show statistical significance of p<0.05. IRR: incidence rate ratio; aIRR: adjusted incident rate ratio; preXDR-TB: pre-extensively drug-resistant tuberculosis; FLQ: fluoroquinolone resistant; SLI: second-line injectable drug resistant; XDR-TB: extensively drug-resistant tuberculosis. #: adjusted for second-line drug resistance, HIV status and whether completed 24 weeks of bedaquiline.